Nundina › Discover calendars › FDA New Drug Approvals calendar › FDA approves Lisraya (brepocitinib tosylate)FDA approves Lisraya (brepocitinib tosylate)27 August 2026The FDA approved Lisraya (brepocitinib tosylate), a drug from Priovant Therap. Form: Tablet, Oral. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application NDA220106.FDA New Drug Approvals calendarMore from this calendar

19 October 2026 - FDA approves Calrezdy (calcuim chloride)

19 October 2026 - FDA approves Cienby (sodium ctirate)

16 October 2026 - FDA approves Yulzety (rivaroxaban)

16 October 2026 - FDA approves Brytly (brytly (apraclonidine))

15 October 2026 - FDA approves Evoxac (cevimeline hydrochloride)